| 1 Global state: 1a. No clinically significant response (as defined by the original studies) |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
0.95 [0.84, 1.08] |
| 2 Global State: 1b. No clinically important change (as defined by the original studies) |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
0.90 [0.66, 1.22] |
| 3 Leaving the study early |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 3.1 due to any reason |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
0.69 [0.37, 1.28] |
| 3.2 due to adverse events |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
1.27 [0.30, 5.44] |
| 3.3 due to inefficacy |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
0.21 [0.05, 0.94] |
| 4 Mental state: 1a. General ‐ average score at endpoint (PANSS total, high=poor) |
1 |
119 |
Mean Difference (IV, Random, 95% CI) |
‐2.70 [‐9.04, 3.64] |
| 5 Mental state: 1b. General ‐ average score at endpoint (BPRS total, high=poor) |
1 |
122 |
Mean Difference (IV, Random, 95% CI) |
‐2.10 [‐5.72, 1.52] |
| 6 Mental state: 2a. Negative symptoms ‐ no clinically important change (less than 50% PANSS negative subscore reduction) |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
0.95 [0.84, 1.08] |
| 7 Mental state: 2b. Negative symptoms ‐ average score at endpoint (PANSS negative subscore, high=poor) |
1 |
122 |
Mean Difference (IV, Random, 95% CI) |
‐0.80 [‐3.00, 1.40] |
| 8 Adverse effects: 1. General ‐ at least one adverse effect |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
0.90 [0.66, 1.22] |
| 9 Adverse effects: 2. Cardiac effects ‐ QTc prolongation |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 10 Adverse effects: 3. Central nervous system ‐ sedation |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
2.86 [0.60, 13.61] |
| 11 Adverse effects: 4. Extrapyramidal effects |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 11.1 akathisia |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
0.63 [0.11, 3.67] |
| 11.2 parkinsonism |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
0.16 [0.02, 1.28] |
| 11.3 use of antiparkinson medication |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
0.59 [0.33, 1.07] |
| 12 Adverse effects: 5. Metabolic ‐ weight ‐ gain of 7% or more of total body weight |
1 |
123 |
Risk Ratio (M‐H, Random, 95% CI) |
2.10 [0.77, 5.67] |
